# Amgen Inc. (AMGN) FY2025 Q1 P&L / Income Statement

- Company: Amgen Inc. (AMGN)
- Period: 2025-01-01 to 2025-03-31
- Filing: Q1 FY2025 10-Q, filed 2025-05-02, accession number 0000318154-25-000020
- Page: https://plicit.ai/financials/amgn/fy2025-q1-income-statement
- Chart image: https://plicit.ai/charts/amgn-fy2025-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2025-01-01 through 2025-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,149,000,000 US dollars
- **Cost of sales**: 2,968,000,000 US dollars
- **Gross profit (calculated)**: 5,181,000,000 US dollars
- **Operating expenses (calculated)**: 4,003,000,000 US dollars
- **Operating income**: 1,178,000,000 US dollars
- **Other income (expense), net (calculated)**: 795,000,000 US dollars
- **Income (loss) before income taxes**: 1,973,000,000 US dollars
- **Provision for income taxes**: 243,000,000 US dollars
- **Net income (loss)**: 1,730,000,000 US dollars
- **Aranesp - UNITED STATES**: 91,000,000 US dollars
- **Aranesp - Non-US**: 249,000,000 US dollars
- **BLINCYTO - UNITED STATES**: 273,000,000 US dollars
- **BLINCYTO - Non-US**: 97,000,000 US dollars
- **EVENITY - UNITED STATES**: 320,000,000 US dollars
- **EVENITY - Non-US**: 122,000,000 US dollars
- **ENBREL - UNITED STATES**: 504,000,000 US dollars
- **ENBREL - Non-US**: 6,000,000 US dollars
- **KRYSTEXXA - UNITED STATES**: 236,000,000 US dollars
- **KRYSTEXXA - Non-US**: 0 US dollars
- **Kyprolis - UNITED STATES**: 216,000,000 US dollars
- **Kyprolis - Non-US**: 108,000,000 US dollars
- **Nplate - UNITED STATES**: 201,000,000 US dollars
- **Nplate - Non-US**: 112,000,000 US dollars
- **Otezla - UNITED STATES**: 343,000,000 US dollars
- **Otezla - Non-US**: 94,000,000 US dollars
- **Other products - UNITED STATES**: 1,270,000,000 US dollars
- **Other products - Non-US**: 377,000,000 US dollars
- **Prolia - UNITED STATES**: 720,000,000 US dollars
- **Prolia - Non-US**: 379,000,000 US dollars
- **Repatha - UNITED STATES**: 343,000,000 US dollars
- **Repatha - Non-US**: 313,000,000 US dollars
- **TEPEZZA - UNITED STATES**: 365,000,000 US dollars
- **TEPEZZA - Non-US**: 16,000,000 US dollars
- **TEZSPIRE - UNITED STATES**: 285,000,000 US dollars
- **TEZSPIRE - Non-US**: 0 US dollars
- **Vectibix - UNITED STATES**: 135,000,000 US dollars
- **Vectibix - Non-US**: 132,000,000 US dollars
- **XGEVA - UNITED STATES**: 360,000,000 US dollars
- **XGEVA - Non-US**: 206,000,000 US dollars
- **Product sales - UNITED STATES**: 5,662,000,000 US dollars
- **Product sales - Non-US**: 2,211,000,000 US dollars
- **Selling, general and administrative**: 1,687,000,000 US dollars
- **Research and development**: 1,486,000,000 US dollars
- **Other**: 830,000,000 US dollars
- **Revenue before reconciliation (calculated)**: 15,746,000,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation.
- **Components above reported revenue (calculated)**: negative 7,597,000,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item.

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue.

## Chart details: Revenue by Product and Service (16 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-q1-income-statement/revenue-by-product-and-service-16-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-q1-revenue-by-product-and-service-16-categories-sankey.png

Income statement for 2025-01-01 through 2025-03-31. View: Product and service (16 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,149,000,000 US dollars
- **Cost of sales**: 2,968,000,000 US dollars
- **Gross profit (calculated)**: 5,181,000,000 US dollars
- **Operating expenses (calculated)**: 4,003,000,000 US dollars
- **Operating income**: 1,178,000,000 US dollars
- **Other income (expense), net (calculated)**: 795,000,000 US dollars
- **Income (loss) before income taxes**: 1,973,000,000 US dollars
- **Provision for income taxes**: 243,000,000 US dollars
- **Net income (loss)**: 1,730,000,000 US dollars
- **Prolia**: 1,099,000,000 US dollars
- **Repatha**: 656,000,000 US dollars
- **XGEVA**: 566,000,000 US dollars
- **ENBREL**: 510,000,000 US dollars
- **EVENITY**: 442,000,000 US dollars
- **Otezla**: 437,000,000 US dollars
- **TEPEZZA**: 381,000,000 US dollars
- **BLINCYTO**: 370,000,000 US dollars
- **Aranesp**: 340,000,000 US dollars
- **Kyprolis**: 324,000,000 US dollars
- **Nplate**: 313,000,000 US dollars
- **TEZSPIRE**: 285,000,000 US dollars
- **Vectibix**: 267,000,000 US dollars
- **KRYSTEXXA**: 236,000,000 US dollars
- **Other products**: 1,647,000,000 US dollars
- **Other revenues**: 276,000,000 US dollars
- **Selling, general and administrative**: 1,687,000,000 US dollars
- **Research and development**: 1,486,000,000 US dollars
- **Other**: 830,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2 categories)

- Page: https://plicit.ai/financials/amgn/fy2025-q1-income-statement/revenue-by-product-and-service-2-categories
- Chart image: https://plicit.ai/charts/amgn-fy2025-q1-revenue-by-product-and-service-2-categories-sankey.png

Income statement for 2025-01-01 through 2025-03-31. View: Product and service (2 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 8,149,000,000 US dollars
- **Cost of sales**: 2,968,000,000 US dollars
- **Gross profit (calculated)**: 5,181,000,000 US dollars
- **Operating expenses (calculated)**: 4,003,000,000 US dollars
- **Operating income**: 1,178,000,000 US dollars
- **Other income (expense), net (calculated)**: 795,000,000 US dollars
- **Income (loss) before income taxes**: 1,973,000,000 US dollars
- **Provision for income taxes**: 243,000,000 US dollars
- **Net income (loss)**: 1,730,000,000 US dollars
- **Product sales**: 7,873,000,000 US dollars
- **Other revenues**: 276,000,000 US dollars
- **Selling, general and administrative**: 1,687,000,000 US dollars
- **Research and development**: 1,486,000,000 US dollars
- **Other**: 830,000,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.